
SOPHiA GENETICS is thrilled to return for ACMG 2026! Visit us at booth #1007 to learn more about our SOPHiA DDM™ and Alamut™ Visual Plus platforms for rare and inherited diseases.
Discover more about our newly launched extended pharmacogenomics (PGx) application, which covers HLA and mitochrondrial regions, with dedicated analytical modules that call variants from SNVs and CNvs to star alleles and CYP2D6/CVP2D7 gene conversion.
Learn more about SOPHiA DDM™ for whole genome sequencing and how our enhanced exome solutions detect challenging variants relevant for carrier screening, hereditary cancer, and PGx in one comprehensive application.
Exhibit Theater 1
Thursday March 12
12:30pm-1:00pm
Future-Ready Genomics: Real World Implementation and Validation from Hereditary Cancer to WGS
Dr. Francisco Perez Blanco, PhD, Chief of Molecular Diagnostics and Biometrics Laboratory, Clinical Alemana de Santiago
Sevana Yaghoubian, MSc - Senior Director of Product Management, SOPHiA GENETICS.
Join this talk to hear real-world clinical experience, implementation, and validation insights, and performance data from SOPHiA DDM™ germline NGS applications, covering hereditary cancer, enhanced exomes, whole-genome sequencing, and pharmacogenomics.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.